The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
NCT04866810 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2026-04-27
Summary
Background:
The gut microbiome is made up microorganisms. These include the good and bad bacteria that live in the digestive tract. Changes in the gut microbiome have been linked to the development of cancer. Researchers want to learn more about the effects of modulating the microbiome with diet and exercise.
Objective:
To see if nutritional intake and physical activity change the gut microbiome in people with melanoma.
Eligibility:
Adults age 18 and older with previously untreated melanoma who will be getting immunotherapy treatment for their disease.
Design:
Participants will not have visits at NIH. They will have phone calls or videocalls.
Participants will be screened with a medical history and medical record review.
Participants will give stool samples. They will fill out surveys about their health, feelings, diet, and exercise.
Participants will be put in 1 of 2 groups. They will follow their group s plan for 4 months. They will be contacted throughout the study.
Intervention Group participants will follow a plant-based, high-fiber diet. They will do at least 150 minutes of moderate or 75 minutes of high-intensity exercise per week. They will have sessions with psychology staff to help them make positive lifestyle changes.
Control Group participants will be taught healthy eating and exercise guidelines. But they will not be asked to change their diet or exercise habits.
All participants will record what they eat in the MyFitnessPal app. They will get a scale to measure their weight each week. They will wear a Garmin(R) physical activity tracker at all times. They can take the tracker off to bathe or shower.
Participation will last for 6 months....
Conditions
Interventions
- BEHAVIORAL
-
Intervention Arm
High fiber, plant based diet + exercise prescription with ACT sessions
- BEHAVIORAL
-
Control
Standard diet and exercise recommendations
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
James L Gulley, M.D. · National Cancer Institute (NCI)
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-25
- Primary Completion
- 2026-10-31
- Completion
- 2027-10-31
Countries
- United States
Study Locations
More Related Trials
-
Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides
NCT00002557 ·Status: UNKNOWN ·Phase: PHASE2
-
Enhancing Cancer Survivorship With Pickleball
NCT06048822 ·Status: COMPLETED ·Phase: NA
-
Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients
NCT00489372 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
NCT06987708 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer
NCT02598726 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
NCT00365209 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
NCT00969085 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
NCT05640843 ·Status: RECRUITING ·Phase: NA
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
NCT06063486 ·Status: RECRUITING ·Phase: PHASE2
-
Examination of Trends in Multiple Myeloma Trial Patient Experiences
NCT05860179 ·Status: NOT_YET_RECRUITING
-
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
NCT00953849 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
NCT00002850 ·Status: COMPLETED ·Phase: PHASE3
-
Everycell's Effect on DNA Damage, Inflammation, and Stress
NCT02032693 ·Status: COMPLETED ·Phase: NA
-
S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911
NCT00896922 ·Status: COMPLETED
-
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
NCT01793051 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997
NCT00899873 ·Status: COMPLETED
-
Etoposide and Celecoxib in Patients With Advanced Cancer
NCT00551005 ·Status: COMPLETED ·Phase: PHASE1
-
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
NCT00665067 ·Status: COMPLETED
-
A Study of Selenomethionine and Myo-inositol(SOLOWAYS_TM) in Patients With Autoimmune Thyroiditis Carrying the DIO2 Thr92Ala Polymorphism
NCT06867913 ·Status: COMPLETED ·Phase: NA
-
The Ambient Light Multiple Myeloma Study
NCT05737732 ·Status: RECRUITING ·Phase: NA
-
Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients
NCT01269203 ·Status: WITHDRAWN ·Phase: PHASE2
-
Lymfit to Improve the Fitness and Quality of Life in Lymphoma Survivors
NCT05257785 ·Status: RECRUITING ·Phase: NA
-
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
NCT00088972 ·Status: TERMINATED ·Phase: PHASE2
-
Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue
NCT01294072 ·Status: RECRUITING ·Phase: NA
-
Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors
NCT05142371 ·Status: COMPLETED ·Phase: NA